PMI Vision
It’s Time to Unsmoke.
There is no question that the best choice for men and women who smoke is to quit cigarettes and nicotine altogether. But many people don’t. In any given year, about 9 out of 10 men and women who are already smoking will continue: those people deserve access to, and information about, better alternatives. That is why we’re building PMI’s future on smoke-free products and focusing our efforts in switching adults, who choose to continue smoking, to our smoke-free products.
In order to achieve this, we are focused on 6 strategic priorities:
About Our Vision
We’ve built the world’s most successful cigarette company, with the world’s most popular and iconic brands. Now we’ve made a dramatic decision. We will be far more than a leading cigarette company. We’re building PMI’s future on smoke-free products that are a much better choice than cigarette smoking. Indeed, our vision – for all of us at PMI – is that these products will one day replace cigarettes.
Why are we doing this? Because we should … We understand the millions of men and women who smoke cigarettes. They are looking for less harmful, yet satisfying, alternatives to smoking. We will give them that choice. We have a commitment to our employees and our shareholders. We will fulfill that commitment by pursuing this long-term vision for success. Society expects us to act responsibly. And we are doing just that, by delivering a smoke-free future. … And because we now can. Success in the cigarette business gives us the resources to pursue our ambitious vision. Thanks to the imagination and perseverance of thousands of people at PMI, we have developed breakthrough products that are smoke-free and enjoyable.
About IQOS
The U.S. Food and Drug Administration (FDA) has authorized the marketing of our flagship electronically heated tobacco system, IQOS, as a modified risk tobacco product (MRTP), which represents a historic opportunity for public health. In doing so, the agency found that issuing an exposure modification order for the IQOS Tobacco Heating System (THS) is appropriate to promote the public health, and is expected to benefit the health of the population as a whole.
This decision demonstrates that IQOS is fundamentally different from combustible cigarettes, and a better choice for adults who would otherwise continue smoking. It follows a review of the extensive scientific evidence package PMI submitted to the FDA in December 2016 to support its MRTP applications.
The FDA’s action authorizes the marketing of IQOS in the USA with the following information:
In April 2019, the agency authorized IQOS for sale in the U.S. through issuance of premarket tobacco product application marketing orders, that deemed marketing the product to be appropriate for the protection of the public health. Now, the FDA has concluded issuing an IQOS exposure modification order is appropriate to promote the public health, and is expected to benefit the health of the population as a whole, taking into account both users and nonusers of tobacco products. Notably, the FDA’s issuance of an exposure modification MRTP order does not mean IQOS is FDA-approved. FDA does not ‘approve’ tobacco products. Further, the FDA’s decision does not mean IQOS is risk-free.
The FDA’s decision is consistent with earlier conclusions of other leading regulatory and scientific bodies, including in the U.K., Germany, and the Netherlands, which have found that the product emits lower levels of harmful toxicants. Furthermore, the FDA’s MRTP authorization shows that IQOS is a fundamentally different product than combustible cigarettes, and must be regulated differently, as the FDA has recognized.
As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to IQOS. We believe that this decision can help to further accelerate the transition of U.S. adults away from cigarettes. We, along with our licensee Altria, are committed to guarding against unintended use and fully support FDA’s focus on protecting youth.
Role Summary
IP Professional who will exercise seasoned judgment and provide guidance to business and functional leaders across the organization with responsibility for performing a variety of moderately complex Intellectual Property (IP) matters, including patent and other IP searches and 3rd party IP investigations and analyses. The output of these analyses will drive identification of risks, as well as opportunities for potential acquisition/licensing partners. The outputs will be shared with the respective IP Law team members and, as circumstances warrant, relevant business colleagues in Product, Consumer, and the M&A team.
Key Responsibilities
Knowledge and experience desired to undertake this role
PMI is an Equal Opportunity Employer PMI Global Services Inc. and PM Global Brands Inc. are a subsidiary of Philip Morris International Inc. Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2022, PMI's smoke-free products are available for sale in 70 markets in key cities or nationwide, and PMI estimates that approximately 13.5 million adults around the world, excluding Russia and Ukraine have already switched to IQOS and stopped smoking.
For more information, please visit www.pmi.com and www.pmiscience.com.
#LIHYBRID
It’s Time to Unsmoke.
$ads={1}
There is no question that the best choice for men and women who smoke is to quit cigarettes and nicotine altogether. But many people don’t. In any given year, about 9 out of 10 men and women who are already smoking will continue: those people deserve access to, and information about, better alternatives. That is why we’re building PMI’s future on smoke-free products and focusing our efforts in switching adults, who choose to continue smoking, to our smoke-free products.
In order to achieve this, we are focused on 6 strategic priorities:
- Developing a long-term product and ecosystem portfolio,
- Building societal support of smoke-free products,
- Growing our smoke-free product categories to scale,
- Delivering product launch & customer service agility,
- Achieving cost and cash leadership, and
- Maintaining leadership in conventional cigarettes.
About Our Vision
We’ve built the world’s most successful cigarette company, with the world’s most popular and iconic brands. Now we’ve made a dramatic decision. We will be far more than a leading cigarette company. We’re building PMI’s future on smoke-free products that are a much better choice than cigarette smoking. Indeed, our vision – for all of us at PMI – is that these products will one day replace cigarettes.
Why are we doing this? Because we should … We understand the millions of men and women who smoke cigarettes. They are looking for less harmful, yet satisfying, alternatives to smoking. We will give them that choice. We have a commitment to our employees and our shareholders. We will fulfill that commitment by pursuing this long-term vision for success. Society expects us to act responsibly. And we are doing just that, by delivering a smoke-free future. … And because we now can. Success in the cigarette business gives us the resources to pursue our ambitious vision. Thanks to the imagination and perseverance of thousands of people at PMI, we have developed breakthrough products that are smoke-free and enjoyable.
About IQOS
The U.S. Food and Drug Administration (FDA) has authorized the marketing of our flagship electronically heated tobacco system, IQOS, as a modified risk tobacco product (MRTP), which represents a historic opportunity for public health. In doing so, the agency found that issuing an exposure modification order for the IQOS Tobacco Heating System (THS) is appropriate to promote the public health, and is expected to benefit the health of the population as a whole.
This decision demonstrates that IQOS is fundamentally different from combustible cigarettes, and a better choice for adults who would otherwise continue smoking. It follows a review of the extensive scientific evidence package PMI submitted to the FDA in December 2016 to support its MRTP applications.
The FDA’s action authorizes the marketing of IQOS in the USA with the following information:
- The IQOS system heats tobacco but does not burn it.
- This significantly reduces the production of harmful and potentially harmful chemicals.
- Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.
In April 2019, the agency authorized IQOS for sale in the U.S. through issuance of premarket tobacco product application marketing orders, that deemed marketing the product to be appropriate for the protection of the public health. Now, the FDA has concluded issuing an IQOS exposure modification order is appropriate to promote the public health, and is expected to benefit the health of the population as a whole, taking into account both users and nonusers of tobacco products. Notably, the FDA’s issuance of an exposure modification MRTP order does not mean IQOS is FDA-approved. FDA does not ‘approve’ tobacco products. Further, the FDA’s decision does not mean IQOS is risk-free.
The FDA’s decision is consistent with earlier conclusions of other leading regulatory and scientific bodies, including in the U.K., Germany, and the Netherlands, which have found that the product emits lower levels of harmful toxicants. Furthermore, the FDA’s MRTP authorization shows that IQOS is a fundamentally different product than combustible cigarettes, and must be regulated differently, as the FDA has recognized.
As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to IQOS. We believe that this decision can help to further accelerate the transition of U.S. adults away from cigarettes. We, along with our licensee Altria, are committed to guarding against unintended use and fully support FDA’s focus on protecting youth.
Role Summary
IP Professional who will exercise seasoned judgment and provide guidance to business and functional leaders across the organization with responsibility for performing a variety of moderately complex Intellectual Property (IP) matters, including patent and other IP searches and 3rd party IP investigations and analyses. The output of these analyses will drive identification of risks, as well as opportunities for potential acquisition/licensing partners. The outputs will be shared with the respective IP Law team members and, as circumstances warrant, relevant business colleagues in Product, Consumer, and the M&A team.
Key Responsibilities
- Based on IP Law needs, business feedback/requests, or pro-active initiative, examine and study competitive patent portfolios to learn more about 3rd-party innovations and publications as part of an effort to assess potential strength, vulnerabilities and scope of coverage relative to PMI.
- Analyzing and assessing data from various internal and external sources in order to drive recommendations relevant to assessing potential IP risks and potential partners or acquisition targets. With respect to potential IP risks, the incumbent partners with internal clients to obtain information and perspectives necessary to create proactive strategies designed to avoid or minimize exposure to legal liability. The identification of potential partners or acquisition targets can be both done pro-actively based on analysis or upon request from other PMI partners such as Product or M&A.
- Given the known PMI product roadmaps and required future technologies, analyze and identify the main competitors (including those beyond the large TMO's) and determine potential future risks and opportunities. Share and validate the outcomes within IP Law and key business partners to drive decisions on next steps.
- Based on requests from PMI partners such as M&A or Product, conduct focused searches on companies and/ or technology areas of interest to evaluate the scope and strength of the IP of potential partners or acquisition targets, ultimately to support a valuation analysis of such targets.
- Support all IP Law processes for organizing and maintaining collections of 3rd-party patents and/or of patent landscapes, search results and IP intelligence data. Continuously look for and implement opportunities for to improve these processes.
- Engaging with IP vendors, search firms or other 3rd party(ies) to conduct or assist in the landscape analysis or search, and/or to assist in the gathering or assessment of IP intelligence from various sources. Continuously seek to increase both our internal and external capabilities to gather such insights in a cost-effective manner.
- Establish ways of working in order to ensure that relevant and appropriate information is timely shared with peers, IP leadership and business partners such as Product Technology & Intelligence, Life Sciences, Strategy and Commercial teams.
- Carry out all activities of the ensuring that PMI Compliance Policies, standards, and laws relating to these activities are fully respected, integrated and understood by stakeholders, and implement adequate processes to ensure the protection of information of a confidential nature.
Knowledge and experience desired to undertake this role
- Juris doctor or equivalent, patent attorney or equivalent, presently seeking to qualify to practice before a patent office or court, or licensed to practice IP law in a locale where PMI operates. [Could be a part-qualified, or newly qualified attorney for one of the roles, and a more senior attorney for the other roles in this area.]
- Advanced degree in relevant scientific/engineering area associated with assigned role.
- 5 - 10 years of concentrated experience which demonstrate an in-depth knowledge and applied understanding of area of expertise.
- Proven comfort with a broad base of different technologies and domains both at chemical/ mechanical and electronics areas.
- Previous managerial and leadership experience preferred.
- Ability to work in a fast-paced environment, handle multiple, conflicting priorities while managing a substantial workload and client expectations.
- Experience of working successfully in a highly results-oriented and performance-driven environment with a focus on excellence.
- Ability to maintain an appropriate perspective regardless of the delicacy or pressure of a situation.
- Robust interpersonal, networking, public speaking, and writing skills, with the confidence and credibility to act quickly, communicate effectively with diplomacy and civility, and command respect of both internal and external audiences.
- Proven ability to think strategically and exercise sound judgment.
- Ability to oversee complex projects and lead them to successful completion in an organized, efficient, and effective manner.
- Ability to lead and work in a multi-disciplinary setting to achieve consensus.
- Extreme attention to detail.
PMI is an Equal Opportunity Employer PMI Global Services Inc. and PM Global Brands Inc. are a subsidiary of Philip Morris International Inc. Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2022, PMI's smoke-free products are available for sale in 70 markets in key cities or nationwide, and PMI estimates that approximately 13.5 million adults around the world, excluding Russia and Ukraine have already switched to IQOS and stopped smoking.
For more information, please visit www.pmi.com and www.pmiscience.com.
#LIHYBRID
$ads={2}
